1Januaz W, Ewa I N, Krzysztof LK, et al. Anthracycline - induced Cardiotoxicity: Clinical Course, Risk Factors, Pathogenesis, Detection and Preventin - review of the Literature[J ]. Med Sci Monit, 2000, 62:411 - 420.
2Pai V B, Nahata M C. Cardiotosicity of Chemotherapeutic Agents: Incidenee, Treatment and Prevention[J]. Drug Saf, 2000, 22 (4) : 263 - 302.
5Fisher P W, Das A. Phosphodiesterase - 5 inhibition with aoldenafil attenuates cardiomyocyte spoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity[J]. Cirulation, 2005, 111(13) : 1601 - 1610.
6Kim S Y, Kim S J, Kim B J, et el. Doxorubicin- induced reative oxygen species generation and intracenular Ca^2+ increase are reciprocally modulated in rat caxdiomyocytes [ J ]. Exp Mol Med, 2006, 38(5) : 535 - 545.
7RviteUi M, Fillippelli A, Rinaldi B, et al. Effects of docsahexaenoic acid on Ca^2+ ; increase induced by doxorubicin in ventricular rat cardiomyocytes[ J ]. Life Sci, 2002, 71(16) : 1905 - 1916.
8Santos D L, Moreno A J. Leino R L, et al. Carvedilol protects against doxorubicin - induced mitochondrial cardiomyopathy [ J ]. Toxlcol Appl Pharmacol, 2002,185(3) :218 - 227.
9Cusack B J, Gambiel H, Musser B, et al. Prevention of chronic anthracydine cardiomyopathy in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism [ J ]. Cancer Chemother Phamacol, 2006, 58(4) : 517 - 526.
